FDA nod for second COVID-19 booster jab in older and immunocompromised patients

The US Food and Drug Administration (FDA) has authorized a second booster dose of either the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) or the Moderna COVID-19 vaccines for older people and certain immunocompromised patients.

This follows the FDA’s previous authorization of a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series.

"Current evidence suggests some waning of protection over time against serious outcomes from COVID-19 in older and immunocompromised individuals"Under the amended emergency use authorizations, a second booster dose of one of the two mRNA vaccines may be administered to people 50 years of age and older at least four months after receipt of a first booster.